Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

• Published in: Oncoimmunology Vol. 10; no. 1; p. 1996000
• Main Authors: Zhao, Ze-Rui, Yang, Chao-Pin, Chen, Si, Yu, Hui, Lin, Yong-Bin, Lin, Yao-Bin, Qi, Han, Jin, Jie-Tian, Lian, Shan-Shan, Wang, Yi-Zhi, You, Jin-Qi, Zhai, Wen-Yu, Long, Hao
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2021; Taylor & Francis Group
• Subjects: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Carcinoma, Non-Small-Cell Lung - drug therapy; chemotherapy; Humans; immunotherapy; Lung cancer; Lung Neoplasms - drug therapy; neoadjuvant; Neoadjuvant Therapy; toripalimab; neoadjuvant; chemotherapy; Lung cancer; immunotherapy; toripalimab

Multimodality treatment provides modest survival benefits for patients with locally advanced (stage III) non-small-cell lung cancer (NSCLC). Nevertheless, preoperative immunotherapy has continuously been shown to be promising in treating resectable NSCLC.This phase 2 trial enrolled patients with AJC...